Abstract
Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54% reduction in the risk of cardiovascular events, mainly driven by a 73% reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 345-349 |
| Number of pages | 5 |
| Journal | Expert Review of Endocrinology and Metabolism |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2013 |
Fingerprint
Keywords
- dipeptidyl peptidase-4 inhibitor
- glimepiride
- linagliptin
- Type 2 diabetes
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
Cite this
Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. / Chilton, Robert J.
In: Expert Review of Endocrinology and Metabolism, Vol. 8, No. 4, 07.2013, p. 345-349.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus
AU - Chilton, Robert J
PY - 2013/7
Y1 - 2013/7
N2 - Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54% reduction in the risk of cardiovascular events, mainly driven by a 73% reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).
AB - Evaluation of: Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet 380(9840), 475-483 (2012). In a recent long-term Phase III comparative trial by Gallwitz et al., the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferior glycemic efficacy compared with glimepiride as add-on therapy to metformin in patients with Type 2 diabetes. Linagliptin was associated with a 54% reduction in the risk of cardiovascular events, mainly driven by a 73% reduction in nonfatal stroke compared with glimepiride. This hypothesis-generating finding may be partly due to the low risk of hypoglycemia inherent to the mechanism of action of linagliptin as well as the relative weight reduction observed with linagliptin compared with glimepiride. The cardiovascular safety profile of linagliptin in direct comparison with glimepiride is being definitively assessed in the CAROLINA trial, due to complete in September 2018 (ClinicalTrials.gov identifier: NCT01243424).
KW - dipeptidyl peptidase-4 inhibitor
KW - glimepiride
KW - linagliptin
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84881111454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881111454&partnerID=8YFLogxK
U2 - 10.1586/17446651.2013.811849
DO - 10.1586/17446651.2013.811849
M3 - Article
AN - SCOPUS:84881111454
VL - 8
SP - 345
EP - 349
JO - Expert Review of Endocrinology and Metabolism
JF - Expert Review of Endocrinology and Metabolism
SN - 1744-6651
IS - 4
ER -